Biopharmaceuticals | NEWLY LAUNCHED

Osteofortil® is the new osteoporosis treatment which contains Teriparatide, a paratohormone analogue, which plays a role in maintaining the calcium and phosphorus balance. Differently from other therapies, Osteofortil® is the only bone building agent capable of inducing both vertebral and extra-vertebral bone regeneration.
OSTEOFORTIL®, Biosidus Teriparatide is produced by bacterial fermentation and is indicated for the treatment and prevention of osteoporosis, a bone disease in which bone mineral density is reduced, leading to an increased risk of fracture. Osteofortil® is be available in single dose PFSs, in boxes containing 30 doses to cover a monthly treatment.